Remdesivir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Remdesivir market is anticipated to expand from USD 4.92 billion in 2025 to USD 7.07 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.23%. Sold under the brand name Veklury, this broad-spectrum antiviral prodrug created by Gilead Sciences works by blocking viral RNA-dependent RNA polymerase to halt viral replication. Market expansion is largely fueled by the persistent demand for potent antiviral treatments against respiratory and other viral illnesses, supported by strong government funding for disease management programs. Additionally, continuous progress in pharmaceutical research plays a key role by improving drug effectiveness and broadening its clinical uses.

Conversely, market growth faces obstacles due to a declining need for COVID-19-targeted antivirals, as severe cases and related hospital admissions have dropped. Other persistent barriers include the development of viral resistance and the high expenses tied to pharmaceutical innovation. Meanwhile, data from the American Medical Association indicates that healthcare expenditures in the United States grew by 7.5% in 2023 to hit $4.9 trillion; this increased spending provides underlying support for the overall pharmaceutical sector and its antiviral segment.

Market Driver

The ongoing prevalence of viral diseases worldwide acts as a major growth engine for the Remdesivir market. The relentless spread of various respiratory pathogens, such as seasonal flu and novel SARS-CoV-2 variants, highlights the urgent need for accessible and potent antiviral therapies. Because these viruses place immense strain on global healthcare infrastructure, there is a strong demand for medications capable of lowering hospitalization rates and preventing severe health complications. The Centers for Disease Control and Prevention noted in February 2026 that the United States saw roughly 290,000 to 450,000 COVID-19-related hospital admissions between October 1, 2024, and July 5, 2025, emphasizing the enduring necessity for drugs like Remdesivir to treat acute infections.

Robust government backing and proactive pandemic readiness programs further stimulate the Remdesivir industry. Nations across the globe are heavily funding the creation and accumulation of antiviral reserves to better manage potential future health emergencies, thereby securing financial support for drug research and procurement. For instance, in February 2026, BARDA introduced the $100 million SMART Antiviral Prize to speed up the creation of broad-spectrum treatments, demonstrating a continued public sector dedication to advanced antiviral solutions. At the same time, overarching investment trends in the pharmaceutical sector impact the availability of these drugs, as seen when Johnson & Johnson announced a 15% cut in its 2025 R&D budget to $14.665 billion in March 2026, illustrating the complex financial ecosystem driving market progress.

Market Challenge

A major obstacle hindering the expansion of the global Remdesivir industry is the dropping demand for antiviral medications tailored specifically to COVID-19. With severe cases of the virus and their corresponding hospital admissions on a steady downward trajectory globally, the urgent requirement for fast-acting treatments like Veklury has notably faded. Consequently, global healthcare networks have scaled back their usage and purchasing of the medication.

The consequences of this waning interest are clearly reflected in Remdesivir's recent financial outcomes. Gilead Sciences reported that Veklury generated $911 million in revenue throughout 2025, which marks a steep 49% drop compared to the previous year's figures. This sharp revenue contraction was mainly caused by the falling number of hospitalizations tied to the virus. Ultimately, this pattern demonstrates that the shifting epidemiological nature of COVID-19 actively reduces the commercial viability of therapies reliant on treating severe viral symptoms.

Market Trends

The international Remdesivir sector is being heavily shaped by shifting post-patent dynamics and a rise in biosimilar rivalry. Even though the primary compound patents for Veklury are valid until the mid-2030s, the market is currently experiencing heightened patent disputes and the end of specific regional monopolies. This environment forces original creators to fiercely protect their intellectual property, just as generic drug makers aggressively seek pathways to enter the market. Consequently, this competitive tension may result in cheaper alternatives becoming available, which could impact the market share and pricing of Remdesivir across multiple regions. Illustrating this IP struggle, JUVE Patent noted that Gilead Sciences initiated a revocation lawsuit in August 2025 at the Central Division's Milan branch against a patent owned by the Chinese Academy of Military Medical Sciences.

Additionally, the rise of combination treatments that pair Remdesivir with other repurposed medications or antivirals is a vital trend transforming the industry. Because viral infections are highly complex, this approach is designed to boost overall effectiveness, widen the range of targeted viruses, and deliver better patient outcomes by leveraging synergistic interactions to defeat drug resistance. These medical strides are intended to push Remdesivir's usefulness past its original applications, ensuring it remains a staple in modern therapeutic strategies. Highlighting this success, an August 29, 2025, publication in J Infect Chemother revealed that using Remdesivir in conjunction with ensitrelvir or nirmatrelvir/ritonavir was successful in 92% of cases (12 out of 13) when utilized as a primary COVID-19 therapy for patients suffering from hematological malignancies.

Key Market Players

• Gilead Sciences, Inc.
• Cipla Limited
• Dr. Reddy’s Laboratories Limited
• Hetero Labs Limited
• Mylan N.V.
• Sun Pharmaceutical Industries Limited
• Zydus Lifesciences Limited
• Jubilant Pharmova Limited
• Aurobindo Pharma Limited
• Fujifilm Toyama Chemical Co., Ltd.

Report Scope

In this report, the Global Remdesivir Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Remdesivir Market, By Dosage Form:

• Lyophilized Solution
• Frozen Solution

Remdesivir Market, By Route of Administration:

• Intravenous
• Inhalation

Remdesivir Market, By Patient Age:

• Geriatric
• Adult
• Pediatric

Remdesivir Market, By Application:

• SARS-CoV-2 (COVID-19)
• MERS-CoV
• Ebola
• SARS-CoV

Remdesivir Market, By Distribution Channel:

• Hospitals
• Clinics
• Drug Stores
• Pharmacies

Remdesivir Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Remdesivir Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.